Austin, May 09, 2025 (GLOBE NEWSWIRE) -- Periodontal Therapeutics Market Size & Trends:
According to SNS Insider, the global Periodontal Therapeutics Market was valued at USD 859.13 million in 2023, is on track to reach USD 1666.11 million by 2032, expanding at a CAGR of 7.62% during the forecast period. The market’s growth is rooted in increasing cases of chronic periodontal diseases, growing awareness of dental hygiene, and advancements in drug delivery technologies.
As the global population ages and urbanizes, the prevalence of gingivitis and chronic periodontitis continues to climb. These gum diseases, often overlooked until late stages, require prolonged treatment and intervention, pushing demand for systemic antibiotics, anti-inflammatory medications, and host-modulating drugs.
Get a Sample Report of Periodontal Therapeutics Market@ https://www.snsinsider.com/sample-request/6765
In the U.S. alone, the market hit USD 246.62 million in 2023 and is expected to reach USD 451.30 million by 2032. High public health spending, early screening programs, and reimbursement policies have significantly contributed to early diagnosis and treatment, making the U.S. a key market driver.
Market Overview
A main driver of the periodontal therapies market is the growing worldwide incidence of periodontal disease, particularly in ageing populations. As more individuals suffer from chronic periodontal diseases, including gingivitis and periodontitis, doctors are looking more and more for efficient medication treatments that can stop the development and improve outcomes. Advances in drug delivery—including host-modulating drugs and targeted antibacterial treatments—are extending therapy options and fueling market expansion. Furthermore, especially in industrialized areas of the world, the treatment barrier has been lowered by the easier access to these drugs via retail as well as hospital pharmacies.
Major component of the market in the United States, awareness campaigns and reimbursement support have resulted in higher rates of diagnosis and quick interventions. Furthermore, cooperation between research institutes and pharmaceutical companies has resulted in the creation of novel medications meant to target particular bacterial species causing gum disease. A tendency toward preventive dentistry and regular dental visits helps the market grow as well by allowing early periodontal disease diagnosis and treatment to be possible.
Key Periodontal Therapeutics Companies Profiled in the Report
- 3M Company (Arestin, Peridex)
- Haleon (Parodontax, Biotène)
- Colgate-Palmolive Company (PerioGard, Colgate PerioCheck)
- Procter & Gamble (Crest Gum Detoxify, Oral-B Gum Care)
- GlaxoSmithKline plc (Parodontax, Corsodyl)
- Sunstar Americas, Inc. (GUM Paroex, GUM Technique Deep Clean Toothbrush)
- Dentsply Sirona (Oraqix, Periochip)
- Pfizer Inc. (Doxycycline Hyclate, Azithromycin)
- Johnson & Johnson Services, Inc. (Listerine Gum Therapy, Listerine Advanced Defence Gum Treatment)
- Valeant Pharmaceuticals (now Bausch Health Companies) (Xepi, Periostat)
- Zila, Inc. (Zilactin, ViziLite Plus)
- Bayer AG (Baytril, PerioAid)
- GC Corporation (Gluco-CheX, Cervitec Plus)
- Acteon Group (Satelec Ultrasonic Scalers, Soprolife Caries Detection)
- MediTeam Dental (ChlorXID, Iodoform Paste)
- P&G Professional Oral Health (Crest + Oral-B) (Gum Care Mouthwash, Pro-Health Gum Detoxify)
- Young Innovations, Inc. (Zooby Prophy Paste, Denticator Prophy Angle)
- Septodont (Septocaine, Alveogyl)
- Nobel Biocare Services AG (NobelActive Implants, GalvoSurge)
- Ivoclar Vivadent AG (Cervitec F, VivaStyle Gum Protect)
Periodontal Therapeutics Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 859.13 million |
| Market Size by 2032 | US$ 1666.11 million |
| CAGR | CAGR of 7.62% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Segment Analysis
By Type:
In 2023, the chronic periodontal disease category led the market with a 35.16% share, mostly because of its frequency and chronic character of the disorder, which calls for continuous treatment intervention. Often underdiagnosed until late stages, chronic periodontitis has driven demand for systemic antibiotics and enzyme-suppressive drugs to reduce tissue damage and slow down disease progression.
The gingivitis segment is expected to expand the most during the forecast period. Better oral care practices, more public knowledge of early-stage gum disease signs, and the growing availability of over-the-counter drugs encouraging early treatment before moving on to more advanced stages account for this expansion. Particularly, younger generations are finding this proactive approach appealing.
By Drug Type:
Doxycycline became the ruling drug category in 2023, holding a market share of 38.19%. It is a preferred treatment drug since it can reduce periodontal pocket depth and stop matrix metalloproteinases (MMPs) that break down connective tissue. Doxycycline's twin anti-inflammatory and antibacterial properties have cemented its place as the accepted treatment.
On the other hand, the most rapidly growing category is projected to be the class of locally administered antimicrobials. Commonly given as gels or fibers placed straight into periodontal pockets, these medications are more in demand because of their targeted action, reduced systemic adverse effects, and improved patient compliance. The growing clinical use of targeted treatment techniques and developments in biodegradable delivery technologies are driving the category.
By Distribution Channel:
Hospital pharmacies retained the highest position in 2023 with a share of 43.10%, mostly due to the prescription-based character of periodontal treatments and the dental professionals working on hospital grounds. The key reasons hospital pharmacies are the first point of contact remain the centralized provision of sophisticated therapies and providing all-around therapy at one location.
Retail pharmacies, nonetheless, are on the move and constitute the fastest-growing channel. The channel's fast expansion is being driven by growing customer need for convenience as well as growing availability of prescription-strength medications and preventive treatments at retail environments. Further enhancing the credibility and accessibility of retail stores were the oral health counseling by chemists and collaboration with dentists offices.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/6765
Periodontal Therapeutics Market Segmentation
By Type
- Gingivitis
- Chronic Periodontal Disease
- Aggressive Periodontal Disease
- Others
By Drug Type
- Doxycycline
- Minocycline
- Chlorhexidine
- Metronidazole
- Other drug types
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
Regional Analysis
North America was the market leader in the global periodontal therapeutics market in 2023, accounting for 38.07% share, resulting from a fast increasing senior population susceptible to periodontal disease, established dental care infrastructure, and supporting reimbursement regulations. Leading in this area with high rates of treatment acceptance, active research programs, and continuous oral health investment is the United States.
Asia-Pacific is expected to experience the fastest growth during the forecast period as a result of expanded access to healthcare, urbanization, and heightened awareness of oral health. China, India, and Japan have seen an upswing in dental consultations, driven in part by the efforts of governments and growing disposable incomes. The region's increasing middle class and evolving dental care ecosystem make it a future growth driver.
Recent Developments in the Periodontal Therapeutics Market
- September 2024 – Haleon, in collaboration with the National Institute for Health and Care Research (NIHR), introduced a new dental care pathway to incorporate screening for Type 2 diabetes as part of dental checkups, to detect more than one million undiagnosed cases using periodontal examination.
- February 2024 – Colgate-Palmolive introduced "PerioGard Advanced Care" gel for gingivitis, addressing initial gum disease with a more powerful chlorhexidine formula for greater tolerability and effectiveness.
- January 2024 – Sunstar Group launched a localized drug delivery system for periodontal pockets in Japan under its GUM brand, utilizing bioresorbable carriers to deliver antimicrobials directly to inflamed sites.
Buy a Single-User PDF of Periodontal Therapeutics Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6765
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Periodontal Diseases (2023)
5.2 Prescription Trends for Periodontal Therapeutics (2023), by Region
5.3 Product and Drug Type Usage Trends (2020-2032).
5.4 Healthcare Spending on Periodontal Care, by Region (2023)
5.5 Technological Advancements in Periodontal Therapeutics (2020-2032)
6. Competitive Landscape
7. Periodontal Therapeutics Market by Type
8. Periodontal Therapeutics Market by Drug Type
9. Periodontal Therapeutics Market by Distribution Channel
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
Related Reports
Dental Regeneration Market Report
Pet Dental Health Market Report
Digital Dentistry Market Report
Dental Biomaterials Market Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
